Navigation Links
Genetics Determine Optimal Drug Dose of Common Anticoagulant
Date:8/21/2007

variants in these genes with initial INR response and other clinical factors, the researchers derived a dosing equation that estimated the therapeutic warfarin dose. The researchers found that these two genes were important in predicting the response to warfarin. Additional factors, such as blood loss during surgery and smoking status, also correlated with therapeutic dose.

Using these data, the researchers developed a therapeutic model that could be used by physicians to refine warfarin dosage with greater accuracy than clinical factors alone. The researchers have made this dosing model publicly available on a free Web site, http://www.warfarindosing.org, and are now validating it in orthopedic and non-orthopedic patients beginning warfarin therapy.

If validated, particularly in patients taking warfarin for reasons other than orthopedic surgery, such as to prevent stroke, this gene-based dosing could predict a safe and effective warfarin dose at the start of treatment, thus minimizing the risks of the current trial-and-error approach.

This work was funded by the National Institutes of Health.

Reporters who wish to receive a copy of the study or arrange an interview with Brian F. Gage, MD, MSc, lead author of the study, may contact Laura Stark at 202-776-0544 or lstark@hematology.org.

The American Society of Hematology (http://www.hematology.org) is the world's largest professional society concerned with the causes and treatment of blood disorders. Its mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems, by promoting research, clinical care, education, training, and advocacy in hematology.

Blood, the official journal of the American Society of Hematolo
'/>"/>

SOURCE American Society of Hematology
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
2. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
3. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
4. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
5. Vion Pharmaceuticals Presents Clinical Data from a Phase II Trial of Cloretazine (VNP40101M) in Elderly AML Patients with Unfavorable Cytogenetics at EHA Meeting
6. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
7. Myriad Genetics Presents Tumor Origin Technology at AACR
8. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
9. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
10. Myriad Genetics Presents Azixas Mode of Action at AACR
11. Expression Genetics, Inc. Announces Successful Completion of Phase I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... -- The North American spine surgery devices market is ... U.S. having the maximum market share. This region is ... The market, by product type, encompasses spinal ... devices, non-fusion implant devices, and spine bone stimulators devices. ... is the largest and fastest-growing segment. Key players ...
(Date:6/3/2015)...  Actavis plc (NYSE: ACT ), a leading global ... and President of Actavis, will provide an overview and update ... Global Healthcare Conference in Rancho Palos Verdes, Calif. ... The presentation will take place on Wednesday, June ... Resort, Rancho Palos Verdes, Calif.  To ...
(Date:6/3/2015)... , June 02, 2015 Research ... addition of the "The Future of Pharmaceutical ... As they are in a desperate need to ... low cost, drug companies have been increasingly utilizing ... their productivity while constantly streamlining their internal operation. ...
Breaking Medicine Technology:Actavis to Present at the Goldman Sachs 36th Annual Global Healthcare Conference 2The Future of Pharmaceutical Outsourcing: 2015 Report 2
... MOUNTAIN VIEW, Calif. , Jan. 28 Omnicell, Inc. (Nasdaq: ... facilities, today announced results for its fourth quarter and year ended ... fourth quarter of 2009 was $54.7 million , up $0.7 ... $7.4 million or 11.9% from the fourth quarter of 2008. ...
... , SAN DIEGO , Jan. 28 ... Phase II clinical trial evaluating CTS-1027 in combination with pegylated ... activity, safety and tolerability of the triple combination will be ... is a significant unmet medical need in HCV patients who ...
Cached Medicine Technology:Omnicell Announces Fourth Quarter and Full-Year 2009 Results 2Omnicell Announces Fourth Quarter and Full-Year 2009 Results 3Omnicell Announces Fourth Quarter and Full-Year 2009 Results 4Omnicell Announces Fourth Quarter and Full-Year 2009 Results 5Omnicell Announces Fourth Quarter and Full-Year 2009 Results 6Omnicell Announces Fourth Quarter and Full-Year 2009 Results 7Omnicell Announces Fourth Quarter and Full-Year 2009 Results 8Omnicell Announces Fourth Quarter and Full-Year 2009 Results 9Omnicell Announces Fourth Quarter and Full-Year 2009 Results 10Omnicell Announces Fourth Quarter and Full-Year 2009 Results 11Omnicell Announces Fourth Quarter and Full-Year 2009 Results 12Omnicell Announces Fourth Quarter and Full-Year 2009 Results 13Omnicell Announces Fourth Quarter and Full-Year 2009 Results 14Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV) 2Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV) 3
(Date:6/3/2015)... Accountable care organizations (ACOs) are increasingly partnering ... worries that these product types were too similar to ... that product-based ACOs will continue to grow in size ... June issue of Atlantic Information Services, Inc.’s (AIS) AIS’s ... that the backlash from HMOs seems to be fading ...
(Date:6/3/2015)... Save On Medical ( http://www.saveonmedical.com ) ... shopping for health care procedures easier for patients on ... look and makes it easier to compare the prices ... , Now, when patients search for the procedure they ... they can see the provider’s price and Docometer quality ...
(Date:6/3/2015)... The National Resident Matching Program Board of Directors ... of Medical Education at the University of California, San Diego ... , “It is an honor to assume the ... Dr. Savoia. “NRMP’s goal is to provide a fair, ... programs, and I welcome the opportunity to guide the organization ...
(Date:6/3/2015)... 2015 Dr. Steven Reisman, a nationally recognized ... ( http://www.newyorkcardiac.com ) located in NYC, announced today the expansion ... practice. In most cases, depending on the level of care ... call, they will be seen by a cardiologist that same ... cardiologist is to ensure that people who have an urgent ...
(Date:6/3/2015)... DC (PRWEB) June 03, 2015 A ... will be honored with a Global Inspire Award at ... recognizes the organization’s outstanding volunteers for their leadership, level ... scale. , The recipients of the Author(s) ... group of authors whose article has made a significant ...
Breaking Medicine News(10 mins):Health News:Product-Based ACOs Are Poised for Growth, Industry Observers Tell AIS Newsletter 2Health News:Product-Based ACOs Are Poised for Growth, Industry Observers Tell AIS Newsletter 3Health News:Save On Medical Launches New Mobile-Optimized Website 2Health News:NRMP Board of Directors Elects New Leadership and Members at its May 2015 Meeting 2Health News:NRMP Board of Directors Elects New Leadership and Members at its May 2015 Meeting 3Health News:NRMP Board of Directors Elects New Leadership and Members at its May 2015 Meeting 4Health News:NYC Cardiologist, Dr. Steven Reisman, Announces Same Day and Evening Appointments 2Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 2Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 3Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 4
... as eunuchs, can now choose a gender of their liking ... //to a special procedure developed at the All India Institute ... 1,100 patients have already given proper gender identities as males ... life, doctors at the premier research and referral institute said. ...
... looking at lactate with a much more positive eye, ... in the immediate //hours after a traumatic brain injury ... right, it could change how emergency room physicians and ... the first critical hours after injury. ,Previous ...
... technology that can quickly screen all 20,000-plus human genes for ... affect how sensitive human cancer cells are to certain chemotherapy ... in the April 12 edition of the journal Nature, researchers ... library of small RNA molecules – the first used by ...
... With allergy season in full bloom, the American Academy of ... of what you can do to cope with the pollen ... specialist can help. // ,This spring, pollen from blooming ... 45 million Americans, causing itching eyes, sneezing, nasal stuffiness, nasal ...
... in erectile dysfunction, decreased libido, anemia, sarcopenia, memory loss, ... ,While a low serum testosterone level is well-known for ... overall physical functioning and fall risk has not been ... of the Archives of Internal Medicine, Orwoll and colleagues ...
... of Queensland men have never been screened for prostate, colorectal ... ,Screening for colorectal cancer currently has stronger scientific evidence for ... skin cancer, but a new study in the Medical Journal ... colorectal cancer test than the other two. ...
Cached Medicine News:Health News:New Procedure Paves Way for Eunuchs to Choose a Gender and Conceive 2Health News:Study Challenges Conventional Treatment of Traumatic Brain Injury 2Health News:Gene Screening Points Way to More Effective Chemotherapy 2Health News:April Showers Bring May Flowers – And Plenty of Pollen, To 2Health News:Low Serum Testosterone Levels Associated With Fall Risk in Elderly Men 2
... IgG Test is an ELISA ... of IgG to Varicella Zoster ... used as,an aid to determine ... status may be determined using ...
The ImmunoWELL Thyroglobulin IgG Quantitative Test is a quantitative enzyme immunoassay (EIA) for screening and detection of autoantibodies against human thyroglobulin in serum and is used as an aid ...
... Screening Panel 4 is an enzyme ... detection of autoantibodies against various specific ... and Sm) in serum, and is ... diagnosis of systemic lupus erythematosus (SLE), ...
The 920M PLUS handheld pulseoximeter provides on-the-spot bloodoximetry and heart rate readings....
Medicine Products: